Lappaconitine hydrobromide(Synonyms: 氢溴酸高乌甲素; Allapinine)

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

Lappaconitine hydrobromide (Synonyms: 氢溴酸高乌甲素; Allapinine) 纯度: ≥95.0%

氢溴酸高乌甲素 (Lappaconitine hydrobromide)是一种天然生物碱类化合物,具有抗心律失常的功效。

Lappaconitine hydrobromide(Synonyms: 氢溴酸高乌甲素; Allapinine)

Lappaconitine hydrobromide Chemical Structure

CAS No. : 97792-45-5

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO ¥660 In-stock
10 mg ¥600 In-stock
50 mg ¥2050 In-stock
100 mg   询价  
200 mg   询价  

* Please select Quantity before adding items.

Lappaconitine hydrobromide 相关产品

相关化合物库:

  • Natural Product Library Plus
  • Drug Repurposing Compound Library Plus
  • FDA-Approved Drug Library Plus
  • Bioactive Compound Library Plus
  • Natural Product Library
  • FDA-Approved Drug Library
  • Anti-Cancer Compound Library
  • Drug Repurposing Compound Library
  • Anti-Cardiovascular Disease Compound Library
  • NMPA-Approved Drug Library
  • FDA Approved & Pharmacopeial Drug Library
  • Alkaloids Library

生物活性

Lappaconitine hydrobromide, a diterpene alkaloid, is a drug for the treatment of cardiac arrhythmias. IC50 value: Target: A natural product for anti-cardiac arrhythmias In vitro: Lappaconitine hydrobromide was found to exert an inhibitory effect on inward tetrodotoxin-sensitive sodium currents without changing their voltage dependence [1]. In vivo: The effect of Lappaconitine hydrobromide on aconitine–induced arrhythmias is due to modulation of genes encoding Na(+)-, K(+)-, Ca(2+)-channels, conducting ionic currents (I(Na), I(to), I(Ks), I(K1), I(CaT)), which are involved in the formation of different phases of the action potential [2]. Lappaconitine hydrobromide was found to be beneficial both in ventricular and supraventricular premature beats. Oral allapinine usually showed its effect 40-60 minutes following its administration, its maximum action being 4-5 hours later, its duration was some 8 hours. The optimal dose of the drug amounted to 75 mg/day [3].

Clinical Trial

分子量

665.61

Formula

C32H45BrN2O8

CAS 号

97792-45-5

中文名称

氢溴酸高乌甲素;高乌甲素氢溴酸盐

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

溶解性数据
In Vitro: 

DMSO : 50 mg/mL (75.12 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.5024 mL 7.5119 mL 15.0238 mL
5 mM 0.3005 mL 1.5024 mL 3.0048 mL
10 mM 0.1502 mL 0.7512 mL 1.5024 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.5 mg/mL (3.76 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (3.76 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH₂O 中,得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂: 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.5 mg/mL (3.76 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (3.76 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中,再用生理盐水定容至 10 mL,完全溶解,澄清透明
  • 3.

    请依序添加每种溶剂: 10% DMSO    90% corn oil

    Solubility: ≥ 2.5 mg/mL (3.76 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (3.76 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

*以上所有助溶剂都可在 Shanghai Jinpan Biotech Co Ltd 网站选购。
参考文献
  • [1]. A. E. Valeev, et al. Effects of allapinine on sodium currents in neurons isolated from the rat trigeminal ganglion and cardiomyocytes. Neurophysiology, 1990, 22 (2): 157-162.

    [2]. Vakhitova IuV, et al. To the mechanisms of antiarrhythmic action of Allapinine. Bioorg Khim, 2013, 39 (1):105-16

    [3]. Abdalla A., et al. Allapinine pharmacodynamics and potential adverse effects. Kardiologiya. 29(7): 29-32

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务